Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 601.2 mg/g (equivalent: protease, qty 2000 ph eur unit; equivalent: amylase, qty 36000 ph eur unit; equivalent: lipase, qty 50000 ph eur unit) - granules, enteric-coated - excipient ingredients: hypromellose phthalate; cetyl alcohol; dimeticone 1000; macrogol 4000; triethyl citrate - creon micro is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 150 mg (equivalent: amylase, qty 8000 ph eur unit; equivalent: lipase, qty 10000 ph eur unit; equivalent: protease, qty 600 ph eur unit) - capsule, enteric - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; macrogol 4000; iron oxide black; triethyl citrate; titanium dioxide; cetyl alcohol; dimeticone 1000; gelatin; iron oxide red; hypromellose phthalate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 300 mg - capsule, enteric - excipient ingredients: gelatin; cetyl alcohol; dimeticone 1000; iron oxide yellow; sodium lauryl sulfate; hypromellose phthalate; macrogol 4000; iron oxide red; triethyl citrate - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - pancreatic extract, quantity: 400 mg (equivalent: protease, qty 1600 ph eur unit; equivalent: lipase, qty 40000 ph eur unit; equivalent: amylase, qty 25000 ph eur unit) - capsule, enteric - excipient ingredients: hypromellose phthalate; iron oxide red; titanium dioxide; sodium lauryl sulfate; macrogol 4000; triethyl citrate; iron oxide black; iron oxide yellow; dimeticone 1000; gelatin; cetyl alcohol - creon is indicated as pancreatic enzyme replacement in paediatric and adult patients with pancreatic exocrine insufficiency (pei). pancreatic exocrine insufficiency is often associated with, but not limited to: cystic fibrosis, chronic pancreatitis, pancreatic surgery, gastrointestinal bypass surgery (eg. bilroth ii gastroenterostomy), ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm)

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - azelastine hydrochloride, quantity: 0.137 mg/actuation (equivalent: azelastine, qty 0.125 mg/actuation) - spray, nasal - excipient ingredients: dibasic sodium phosphate dodecahydrate; disodium edetate; hypromellose; purified water; citric acid; sodium chloride - for the symptomatic treatment of seasonal allergic rhinitis, perennial allergic rhinitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - azelastine hydrochloride, quantity: 0.5 mg/ml (equivalent: azelastine, qty 0.457 mg/ml) - eye drops - excipient ingredients: sodium hydroxide; benzalkonium chloride; water for injections; disodium edetate; hypromellose; sorbitol solution (70 per cent) (crystallising) - eyezep is indicated for the treatment and prevention of the symptoms of seasonal and non-seasonal (perennial) allergic conjunctivitis in adults and children 4 years and older.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin sodium, quantity: 1060 mg (equivalent: amoxicillin, qty 1000 mg) - injection, powder for - excipient ingredients: - fisamox is indicated in the treatment of infections due to susceptible strains of the organisms listed below. fisamox powder for injection is intended for use where the patients condition precludes the administration of the oral form. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however in emergency cases where the causative organism has not yet been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia (bacterial) h. influenzae, e. coli (see microbiology), p. mirabilis, streptococci, s. pneumoniae, s. faecalis and salmonella typhi. skin and skin structure streptococci, non-beta-lactamase-producing staphylococci, e. coli (see microbiology). respiratory, acute and chronic h. influenzae, streptococci, s. pneumoniae, non-beta-lactamase-producing staphylococci, e. coli (see microbiology). genito-urinary tract (complicated and uncomplicated), acute and chronic e. coli (see microbiology), p. mirabilis and s. faecalis. gonorrhoea n. gonorrhoeae (non-beta-lactamase-producing) prophylaxis of endocarditis fisamox may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with prosthetic heart valves or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - mebeverine hydrochloride, quantity: 135 mg - tablet, sugar coated - excipient ingredients: purified talc; acacia; gelatin; povidone; magnesium stearate; carnauba wax; potato starch; sucrose; lactose monohydrate - colofac tablets are indicated in the management of the irritable bowel syndrome ( 'irritable colon', 'spastic colon', 'functional bowel disorders', 'spastic constipation', 'nervous diarrhoea'). colofac is used to treat the symptoms of this condition- i.e. abdominal pain and cramps, persistent, non-specific diarrhoea (with or without alternating constipation) and flatulence.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cyproheptadine hydrochloride sesquihydrate, quantity: 4.3 mg (equivalent: cyproheptadine hydrochloride, qty 4 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; magnesium stearate; pregelatinised maize starch; lactose monohydrate; maize starch - use as an antiallergic-antipruritic agent and relief of migraine and vascular types of headaches.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 7 august 1996: ceclor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including phryngitis, tonsillitis and acute bacterial sinusitis; community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tact infections, including cystitis; skin and skin structure infections. note: 1. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. ceclor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of ceclor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be performed. therapy may be started while awaiting the results of these studies. once these results become available, antimicrobial therapy should be adjusted accordingly.